Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term continuous methimazole versus radioactive iodine for Graves' hyperthyroidism
IRCT201009224794N1Phase 3Completed
- Sponsor
- Research Institute for Endocrine Sciences
- Start
- Mar 1990
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, open-label trial of methimazole, iodine-131 and levothyroxine sodium in Graves' disease and hyperthyroidism (3 arms), sponsored by Research Institute for Endocrine Sciences. Primary endpoint: Relapse of overt hyperthyroidism after treatment discontinuation. Started Mar 1990; status: completed.
02
Drugs
methimazoleiodine-131levothyroxine sodium
03
Conditions
Graves' diseasehyperthyroidism
Beyond the preview
Go deeper on IRCT201009224794N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201009224794N1.